A multi-institutional retrospective study of dacomitinib in rechallenge setting for patients with EGFR mutation (TOPGAN2020-02)

A multi-institutional retrospective study of dacomitinib in rechallenge setting for patients with EGFR mutation (TOPGAN2020-02) - TOPGAN2020-02

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000042975

Enrollment

Registered

2021-01-15

Start date

2020-06-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer(EGFR mutation +)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who received dacomitinib therapy as rechallenge setting between January 2019 and October 2020

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
To evaluate the clinical coarse, the efficacy and safety, of dacomitinib for patients with EGFR mutation positive non-small cell lung cancer PFS	—

Secondary

Measure	Time frame
OS ORR AE	—

Countries

Japan

Contacts

Public ContactHISASHI TANAKA

Hirosaki University garduate school of medicine Respiratory medicine

xyghx335@gmail.com0172395468

Outcome results